Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Mar 12, 2019
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, its Lead Immuno-Oncology Product Candidate
Mar 05, 2019
Compugen to Present at the Cowen and Company 39th Annual Health Care Conference
Research and Development
Our optimized process for predictive discovery of novel drug targets
Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Apr 02, 2019
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, AACR 2019 Annual Meeting
Mar 11, 2019
Compugen Presentation at the Cowen and Company 39th Annual Health Care Conference
Feb 28, 2019
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, The ASCO-SITC Clinical Immuno-Oncology Symposium
San Francisco, CA
Click here for more info about partnering with Compugen